About Therapanacea SAS
TheraPanacea SAS is a medical technology company founded in 2017 that harnesses artificial intelligence to develop cutting-edge software for more efficient and precise cancer care. The company's flagship product, ART-Plan™, is a fully AI-powered, web-based solution for radiotherapy that optimizes every step of the treatment process from preparation to follow-up. The platform includes multiple modules: Annotate for automated contouring of over 250 organs-at-risk and lymph nodes, SmartFuse for high-precision image fusion, MR-Box for MR-only workflow with pseudo-CT generation, and AdaptBox for AI-driven adaptive radiotherapy decision support. TheraPanacea's solutions enable radiation oncology teams to save up to 93% of contouring time, delivering full-body expert-like contours in just 3 minutes. The company serves over 300 cancer centers across Europe and has supported treatment for more than 1.5 million patients. Beyond radiotherapy, TheraPanacea is developing ART-Omics™, an AI-powered radiomics platform for biomarker discovery to support pharmaceutical companies in drug development. The company's mission is to improve the quality of life of each patient by enabling healthcare providers to design smarter treatment plans, work more effectively, and reduce toxic side effects. TheraPanacea offers pioneering holistic approaches for cancer research and treatment based on multi-scale integration of medicine, information theory, data curation, and computational medicine.
Mission & Story
Mission
Our mission is to improve the quality of life of each patient by enabling health care providers to design smarter treatment plans, work more effectively, and reduce toxic side effects.
Founding Story
TheraPanacea was created in 2017 as an award-winning medical technology company with a vision to exploit state-of-the-art research technology to accelerate healthcare's transition towards predictive, evidence-driven, adaptive treatment planning and delivery.
Clinical Focus
Medical conditions and clinical areas addressed by Therapanacea SAS.
Who It Serves
Milestones & Awards
Recent Milestones
Finalist for INPI's Research Award (October 2025). Scientific presentations at ESTRO 2025 and ESTRO 2026. Development of new modules including SmartPlan (AI-powered treatment planning), TumorBox (brain tumor autosegmentation), and BrachyBox (brachytherapy delineation).
Awards & Recognition
Multiple prestigious distinctions and prizes since creation. Finalist for INPI's Research Award 2025. Award-winning medical technology company.
Key Partnerships
Social & Media
Latest Updates
Company Details
- Founded
- 2017
- Headquarters
- Paris, Île-de-France, France
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.